Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial

Aditya H. Gaur, James S. McCarthy, John C. Panetta, Ronald H. Dallas, John Woodford, Li Tang, Amber M. Smith, Tracy B. Stewart, Kristen C. Branum, Burgess B. Freeman, Nehali D. Patel, Elizabeth John, Stephan Chalon, Shelley Ost, Ryan N. Heine, Julie L. Richardson, Robbin Christensen, Patricia M. Flynn, Yvonne Van Gessel, Branko MitasevJörg J. Möhrle, Fabian Gusovsky, Lidiya Bebrevska, R. Kiplin Guy

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)964-975
Number of pages12
JournalThe Lancet Infectious Diseases
Volume20
Issue number8
DOIs
StatePublished - Aug 2020

ASJC Scopus Subject Areas

  • Infectious Diseases

Cite this